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exploring the role of CDI coming from the community into 
the hospital have become increasingly popular (9); how-
ever, to the best of our knowledge, only 1 modeling study 
described CDI dynamics within the wider community 
(10). Although this approach is innovative, we acknowl-
edge some limitations. Medication exposure was used as a 
proxy, based on the average prescription in the community, 
and it cannot be applied to the individual patient. In addi-
tion, we were unable to adjust the regression model for 
the presence of concurrent medical conditions and other 
unmeasured confounders.
Exposure to medications, particularly antimicrobial 
drugs, probably influences CA-CDI pathogenesis (2). How-
ever, our community-based assessment indicates that a more 
holistic exploration is needed to identify alternative factors 
driving increases in CA-CDI cases in the wider population.
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To the Editor: In 2015, an outbreak of multidrug- 
resistant Campylobacter coli was documented in Montreal, 
Quebec, Canada. We report results of an epidemiologic 
and molecular investigation suggesting a sexually trans-
mitted enteric infection among men who have sex with 
men (MSM).
The ethics committee of Centre Hospitalier de 
l’Université de Montréal approved the research. During 
January 14–February 7, 2015, six men 35–62 years of age 
were documented with an enteric, erythromycin-, tetracy-
cline- and ciprofloxacin-resistant C. coli pulsovar 15 infec-
tion. All 6 men had diarrhea; 5 had abdominal pain; 1 had 
fever >39°C; 1 had blood in feces; and 1 had vomiting. No 
extraintestinal focus was documented in these patients. 
Five men were evaluated in the outpatient clinic or 
emergency department; 1 man was hospitalized for 3 days. 
Five patients were treated with an antimicrobial agent. 
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Three were treated orally for 4–7 days: 1 with ciprofloxa-
cin, 1 with azithromycin, and 1 with both drugs. One pa-
tient was treated for 3 days with intravenous ceftriaxone 
and vancomycin followed by 10 days of amoxicillin for 
simultaneous Streptococcus pneumoniae septicemia. One 
man was treated with 1 intramuscular ceftriaxone dose, 
doxycycline for 21 days, and intravenous ertapenem for 3 
days for proctitis and enterocolitis. All patients recovered 
with treatment (in vitro susceptible or resistant agent) or 
without treatment.
The 6 men reported to be MSM. The week before 
symptom onset, 4 men reported having had unprotected 
sex, 2 in bathhouses. Before the C. coli incubation period 
and after the outbreak started, 1 of these 2 men had traveled 
to the Caribbean but did not have sexual relations there. 
These men were not explicitly linked to each other. Five 
men were HIV positive; 1 was HIV negative. The 5 HIV-
positive men had CD4 counts ranging from 210 to 1,150 
× 106 cells/L and HIV viral load of <40 copies/mL. Since 
2010, the 6 men had 15 documented sexually transmitted 
infections (STIs) other than HIV, 1–3 (median 3) STIs per 
patient: 4 Treponema pallidum infections; 3 Chlamydia 
trachomatis infections (1 rectal C. trachomatis serovar 
L2b, a lymphogranuloma venereum agent); 4 Neisseria 
gonorrhoeae infections; 3 Shigella spp. infections; and 1 
C. jejuni infection.
The Laboratoire de Santé Publique du Québec (LSPQ, 
Sainte-Anne-de-Bellevue, QC, Canada) confirmed the 6 C. 
coli infections using cpn60 gene sequencing (1). Drug sus-
ceptibility testing was done by using disk diffusion method 
for nalidixic acid and Etest (AB Biodisk, Solna, Sweden) 
for 12 other agents (1–3).The susceptibility and resistance 
breakpoints were Clinical and Laboratory Standards Insti-
tute Campylobacter, Enterobacteriaceae, and other break-
points as reported (1–4). The 6 C. coli pulsovar 15 were 
resistant to erythromycin, azithromycin, clarithromycin, 
clindamycin, tetracycline, ciprofloxacin, nalidixic acid, 
ampicillin, and cefotaxime. All isolates were susceptible 
to amoxicillin/clavulanic acid, imipenem, ertapenem, and 
gentamicin. The 6 isolates were β-lactamase positive in <1 
min with nitrocefin disk. Pulsed-field gel electrophoresis, 
done at LSPQ as described by PulseNet Canada proce-
dures (1), showed that the 6 isolates presented the same 
pattern with both SmaI and KpnI enzymes designed puls-
ovar 15 (Figure).
These phenotypic, epidemiologic, and molecular data 
confirmed a cluster of an erythromycin-, tetracycline-, 
and ciprofloxacin-resistant C. coli pulsovar 15 infections 
in Montreal, Quebec, Canada, during January–February 
2015. Epidemiologic data suggested enteric STIs. All 6 pa-
tients reported being MSM; 4 reported having unprotected 
sex the week before symptom onset; 5 were HIV-positive; 
the 6 men had 15 other STIs; and no food was suspected to 
be the source of the infection. 
Campylobacter is an important human enteropathogen 
bacterium, and C. coli is the second most frequently report-
ed species (4–6). Few C. coli clusters have been reported, 
and the outbreaks caused by this Campylobacter species 
might be underestimated (1,7). At the LSPQ, a high het-
erogeneity was documented in C. coli isolates character-
ized routinely from suspected outbreaks during 2011–2015 
(Figure) (1; this study). The erythromycin, tetracycline, and 
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Figure. Pulsed-field gel 
electrophoresis patterns of 
Campylobacter coli with SmaI 
(18 isolates) and KpnI  
(6 isolates) enzymes tested in 
study of C. coli outbreak among 
6 men in Quebec, Canada, 
2011–2015. p, pulsovar. Scale 
bar indicates percentage 
similarity.
ciprofloxacin susceptibilities were epidemiologic markers 
in this study and in previous studies (1,8). The presence of a 
strong β-lactamase with resistance to ampicillin was also a 
marker in this study; epidemic C. jejuni and C. coli isolates 
were β-lactamase negative with susceptibility to ampicillin 
in previous outbreaks in MSM (1,8). Higher proportions of 
C. coli isolates are erythromycin- and multidrug-resistant 
than are C. jejuni isolates (4,6). When indicated, the proper 
antimicrobial treatment of enteric erythromycin- and cip-
rofloxacin-resistant Campylobacter spp. is not known be-
cause no clinical studies have been done for infections with 
such isolates, but tetracycline or amoxicillin/clavulanic 
acid can be used if isolates are susceptible in vitro (1,8; 
this study).
MSM should be counseled about preventing STIs, 
including enteric infections. Barriers should be used dur-
ing genital, oral, and anal sex, and genital and hand wash-
ing before and after sex should be done (9,10). Our study 
increases evidence of clusters of Campylobacter STIs in 
MSM (1,8).
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To the Editor: In an article that reviews evidence of a 
plot to use plague to break the siege of Candia during the 
Venetian–Ottoman War of the 17th century, Dr. Thalassi-
nou and her colleagues (1) identify an incident previously 
unknown to historians of biological warfare. However, the 
authors’ effort to broaden the context for biological weap-
onry is undermined by a reference to an often repeated al-
legation for which no credible evidence exists: namely, that 
during a siege occurring in the Swedish–Russian War of 
1710, the Russians catapulted bodies of plague victims into 
the Swedish-held city of Reval.
Danish historian Karl-Erik Frandsen conducted a 
careful study of the plague outbreak affecting the Baltic 
area during 1709–1713 and found no evidence to sup-
port this allegation (2). Plague was first detected in Re-
val on August 10, 1710, while the army from Russia was 
still approaching the city. Reval was not besieged, and the 
Russians merely camped outside the city while attempt-
ing to isolate it. The army dumped corpses into a stream 
that flowed into Reval, but evidence does not show that 
the dead were plague victims, nor does evidence exist that 
clarifies whether the intent was contamination of the water 
supply or disposal of bodies. Original accounts provide no 
evidence to suggest that Russians hurled bodies into the 
city, much less plague-infected bodies. Frandsen estimates 
that about three quarters of the 20,000 persons in Reval 
died during the outbreak (2).
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